J&J subsidiary files for third bankruptcy to settle talc claims
A Johnson & Johnson subsidiary filed for bankruptcy in its third attempt to settle a vast majority of cases alleging its talc products caused cancer. The $8 billion settlement plan would resolve...
View ArticleA small startup is challenging Epic's control over patient health records
A software startup has sued Epic on antitrust grounds, arguing that the electronic health records giant has orchestrated a scheme to destroy the startup’s business and maintain its monopoly over...
View ArticleClik here to view.
Biogen, UCB declare Phase 3 lupus win and prep a second trial, but details...
Biogen and UCB said Tuesday morning that data from a Phase 3 study for the lupus program dapirolizumab pegol were strong enough to convince it to launch a second pivotal trial to confirm the benefit...
View ArticleFlagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first...
The AI-focused biotech Generate:Biomedicines announced another pharma partnership Tuesday, agreeing to work on several protein therapies with the Swiss drugmaking giant Novartis. Novartis will pay $50...
View ArticleConstructive Bio raises $58M for synbio work, and Nobel laureate joins board
A UK-based synthetic biology startup has brought in $58 million from private investors to fund its work engineering cell systems that can manufacture new and existing molecules. The company, called...
View ArticleClive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with...
Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first clinical data just a few months after emerging with $290 million and a broad...
View ArticleHouse passes reauthorization of rare pediatric voucher program
The US House of Representatives on Monday afternoon unanimously passed a wide-ranging bill via voice vote that will reauthorize the rare pediatric priority review voucher program through 2029, among...
View ArticleClik here to view.
Updated: Gene therapy maker bluebird bio cuts costs again, lays off staff
Bluebird bio is cutting more jobs and expenses in the latest bid to manage its fragile finances as it supports the launch of its sickle cell gene therapy Lyfgenia. The company announced earlier Tuesday...
View ArticleHealth plan startup Centivo raises $75M
Centivo, a startup that sells health insurance to employers, raised $75 million in fresh funds months after it bought a virtual primary care startup to use in its offerings. The startup’s goal is to...
View ArticleSanofi hires Mike Quigley as next chief scientist, internal memo says
Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma’s next chief scientific officer, Endpoints News has learned. Quigley will replace Frank...
View ArticleClik here to view.
Samsara adds three venture partners to help steer and advise portfolio companies
Biotech investment firm Samsara BioCapital has added three new venture partners in recent months to expand its network, support first-time CEOs in its portfolio and guide more companies by way of board...
View ArticleClik here to view.
Checking up on past Endpoints 11 winners: Who went public, who got bought and...
You win some, you lose some — that’s the risk of trying to predict the next hot biotechs. Since 2018, the Endpoints 11 awards have identified startups with the right ingredients to become a great drug...
View ArticlePCI Pharma earmarks $356M to expand injectable device capacity in US and Ireland
PCI Pharma Services is pouring $365 million to expand its US and Irish footprint for commercial and clinical packaging of drug-device products to meet “evolving” market needs. The CDMO, which...
View ArticleCapricor to begin filing DMD drug with FDA next month; Surrozen’s $10M milestone
Plus, news about Adaptimmune, Roche, LIfT BioSciences, VerImmune, and Revance Therapeutics: Capricor Therapeutics to file Duchenne cardiomyopathy treatment with the FDA: The San Diego-based biotech in...
View ArticleClik here to view.
Wave rides new Phase 2 DMD data as it sets sights on accelerated approval
Wave Life Sciences said new Phase 2 biomarker data for its exon-skipping therapy are promising for certain patients with Duchenne muscular dystrophy, and it plans to discuss accelerated approval plans...
View ArticleRegeneron hits setback in Eylea patent battle with Amgen
Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its blockbuster eye treatment Eylea. While Regeneron previously defended itself in...
View ArticleSIGA fires former NYC Covid advisor after secret recordings detail...
Biotech company SIGA Technologies has fired chief medical officer Jay Varma, days after the publication of secret recordings of the former New York City public health advisor talking about how he...
View ArticleNovo Nordisk CEO skeptical of PBM promises in Senate hearing on weight loss...
Sen. Bernie Sanders (I-VT) told Novo Nordisk CEO Lars Fruergaard Jørgensen that three major pharmacy benefit managers have agreed not to penalize the company for lowering the list prices of its popular...
View ArticleFDA adcomm will reexamine approval of checkpoint inhibitors in two cancers...
The FDA’s Oncologic Drugs Advisory Committee will meet Thursday to discuss whether several immune checkpoint inhibitor drugs should come with narrower indications in two cancers, based on emerging data...
View ArticleClik here to view.
Amgen reports dual Phase 3 wins in atopic dermatitis and myasthenia gravis
Amgen released data from two pivotal trials on Tuesday that showed its experimental drug rocatinlimab succeeded in a Phase 3 test in atopic dermatitis, while its approved drug Uplizna also yielded...
View Article